Acticor Sky VR-T 481989; Rivacor Sky VR-T 481984; Rivacor Rise VR-T 482020; Rivacor Aura VR-T 482015; Acticor Sky VR-T D
Biotronik, Inc. · Decision date Oct 9, 2026
What did the FDA approve?
The FDA record P980023/S149, dated October 9, 2026, is a real-time process supplement to the original PMA P980023 for Biotronik's implantable cardioverter defibrillator line (product code LWS, non-CRT). The listed devices are Acticor Sky VR-T 481989, Rivacor Sky VR-T 481984, Rivacor Rise VR-T 482020, Rivacor Aura VR-T 482015 and Acticor Sky VR-T D. The supplement reason is a change to design, components, specifications or material, and the decision is approval.
The source statement confines the change to a battery separator pocket material change and a new additive to the battery electrolyte. It does not name the specific materials, additive chemistry, affected battery model or which of the listed devices the change covers. A supplement modifies a subset of the original PMA rather than re-approving the whole system, and the reported purpose is not independent proof of safety or clinical effectiveness.
The database entry supplies no manufacturing site, implementation timing or post-change performance data, so those details remain unavailable.
FDA approval order statement
battery separator pocket material change and new additive to battery electrolyte.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 9, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P980023/S149
- Regulatory pathway
- PMA supplement
- Applicant
- Biotronik, Inc.
- Product code
- LWS
- Decision code
- APPR
- Decision date
- Oct 9, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implantable cardioverter defibrillator (non-CRT).
- Applicant
- Biotronik, Inc.
- Product code
- LWS
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P980023. Subsequent supplements may change the device or its indications.
FDA decision timeline
P980023 · Original PMA
PHYLAX IMPLANTABLE CARDIOVERTER DEFIBRILLATOR SYSTEM
P980023/S149 received
Application receipt date recorded by FDA.
P980023/S150 · Related supplement
Pamira S 60; Pamira S 65; Pamira S 75; Pamira SD 60/16; Pamira SD 65/16; Pamira SD 65/18; Pamira SD 75/18; Pamira S DX 6
P980023/S146 · Related supplement
Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Rivacor Aura VR-T, Acticor Sky VR-T DX, Rivacor Sky VR-T DX, Riva
P980023/S140 · Related supplement
Ilivia Neo 7 VR-T DX 429530; Intica Neo 7 VR-T DX 429559; Intica Neo 5 VR-T DX 429569
P980023/S151 · Related supplement
Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Rivacor Aura VR-T, Acticor Sky VR-T DX, Rivacor Sky VR-T DX, Riva
P980023/S149 · FDA decision
Real-Time Process
P980023/S152 · Related supplement
Ilivia Neo 7 VR-T DX DF-1 ProMRI, Ilivia Neo 7 VR-T DF-1 ProMRI, Intica Neo 7 VR-T DX DF-1 ProMRI, Intica Neo 7 VR-T DF-
P980023/S153 · Related supplement
Ilivia Neo 7 VRT DX, Intica Neo 7 VRT DX, Intica Neo 5 VRT DX, Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Ri
Timeline entries are records held by MedtechLedger for P980023. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P980023
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik, Inc. | PMA approval | Oct 27, 1998 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 10, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 17, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 25, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 25, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA |
Explore the linked device profile
Other records with product code LWS
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Nov 5, 2026 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Nov 4, 2026 | FDA | |
Cobalt MRI ICD, Cobalt XT MRI ICD, Crome MRI ICDP980016/S967 | Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 29, 2026 | FDA |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 5, 2026 | FDA | |
| BOSTON SCIENTIFIC CORPORATION | PMA supplement | Oct 2, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6024 Jean Rd., Lake Oswego, OR, 97035
Sources and methodology
- Original FDA record: P980023/S149
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




